EP3803390B1 - Method for detecting urinary tract infections and sample analysis - Google Patents
Method for detecting urinary tract infections and sample analysis Download PDFInfo
- Publication number
- EP3803390B1 EP3803390B1 EP19811477.9A EP19811477A EP3803390B1 EP 3803390 B1 EP3803390 B1 EP 3803390B1 EP 19811477 A EP19811477 A EP 19811477A EP 3803390 B1 EP3803390 B1 EP 3803390B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- agmatine
- samples
- sample
- diagnosing
- isocratic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000019206 urinary tract infection Diseases 0.000 title claims description 66
- 238000000034 method Methods 0.000 title claims description 61
- 238000004458 analytical method Methods 0.000 title claims description 36
- QYPPJABKJHAVHS-UHFFFAOYSA-P agmatinium(2+) Chemical compound NC(=[NH2+])NCCCC[NH3+] QYPPJABKJHAVHS-UHFFFAOYSA-P 0.000 claims description 104
- QYPPJABKJHAVHS-UHFFFAOYSA-N Agmatine Natural products NCCCCNC(N)=N QYPPJABKJHAVHS-UHFFFAOYSA-N 0.000 claims description 103
- 210000002700 urine Anatomy 0.000 claims description 81
- 238000002347 injection Methods 0.000 claims description 36
- 239000007924 injection Substances 0.000 claims description 36
- 239000002904 solvent Substances 0.000 claims description 28
- 239000002207 metabolite Substances 0.000 claims description 27
- 238000010828 elution Methods 0.000 claims description 26
- 238000004811 liquid chromatography Methods 0.000 claims description 21
- 230000003115 biocidal effect Effects 0.000 claims description 17
- 241000588921 Enterobacteriaceae Species 0.000 claims description 12
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 claims description 11
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 9
- 239000001963 growth medium Substances 0.000 claims description 9
- 239000003242 anti bacterial agent Substances 0.000 claims description 7
- 238000004949 mass spectrometry Methods 0.000 claims description 7
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 5
- 235000019253 formic acid Nutrition 0.000 claims description 5
- 238000011534 incubation Methods 0.000 claims description 5
- 241000741267 Enterobacteriaceae bacterium Species 0.000 claims 1
- 239000000523 sample Substances 0.000 description 88
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 64
- VHRGRCVQAFMJIZ-UHFFFAOYSA-N cadaverine Chemical compound NCCCCCN VHRGRCVQAFMJIZ-UHFFFAOYSA-N 0.000 description 56
- 238000004587 chromatography analysis Methods 0.000 description 52
- 239000012071 phase Substances 0.000 description 43
- 239000005700 Putrescine Substances 0.000 description 31
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- 239000012491 analyte Substances 0.000 description 25
- 241000588724 Escherichia coli Species 0.000 description 21
- 238000001514 detection method Methods 0.000 description 20
- 230000002503 metabolic effect Effects 0.000 description 16
- 238000003556 assay Methods 0.000 description 15
- 150000002500 ions Chemical class 0.000 description 14
- 244000005700 microbiome Species 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 12
- 230000001629 suppression Effects 0.000 description 12
- 239000000203 mixture Substances 0.000 description 11
- 241000588749 Klebsiella oxytoca Species 0.000 description 9
- 241000588747 Klebsiella pneumoniae Species 0.000 description 9
- 238000000926 separation method Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 241000588923 Citrobacter Species 0.000 description 8
- 241000588914 Enterobacter Species 0.000 description 8
- 239000003755 preservative agent Substances 0.000 description 8
- 241000588748 Klebsiella Species 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 7
- 230000005526 G1 to G0 transition Effects 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 6
- 239000004327 boric acid Substances 0.000 description 6
- 238000013375 chromatographic separation Methods 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 230000002335 preservative effect Effects 0.000 description 6
- 241000588770 Proteus mirabilis Species 0.000 description 5
- 206010040047 Sepsis Diseases 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- 208000037815 bloodstream infection Diseases 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000000813 microbial effect Effects 0.000 description 5
- 239000013610 patient sample Substances 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 241000588915 Klebsiella aerogenes Species 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000012472 biological sample Substances 0.000 description 4
- 238000009629 microbiological culture Methods 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 239000002699 waste material Substances 0.000 description 4
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 3
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 3
- 241001494522 Citrobacter amalonaticus Species 0.000 description 3
- 241000580513 Citrobacter braakii Species 0.000 description 3
- 241000949030 Citrobacter farmeri Species 0.000 description 3
- 241000588919 Citrobacter freundii Species 0.000 description 3
- 241000588917 Citrobacter koseri Species 0.000 description 3
- 241000588697 Enterobacter cloacae Species 0.000 description 3
- 241000588769 Proteus <enterobacteria> Species 0.000 description 3
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 3
- 239000001099 ammonium carbonate Substances 0.000 description 3
- 238000004891 communication Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 229940092559 enterobacter aerogenes Drugs 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000003908 quality control method Methods 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 229930186147 Cephalosporin Natural products 0.000 description 2
- 206010061126 Escherichia infection Diseases 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 229940124587 cephalosporin Drugs 0.000 description 2
- 150000001780 cephalosporins Chemical class 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000006114 decarboxylation reaction Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 208000020612 escherichia coli infection Diseases 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 229940124307 fluoroquinolone Drugs 0.000 description 2
- -1 for example Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 description 1
- 229930091051 Arenine Natural products 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000034801 Enterobacteriaceae Infections Diseases 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical class NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 239000004280 Sodium formate Substances 0.000 description 1
- HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 238000009635 antibiotic susceptibility testing Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 208000033847 bacterial urinary tract infection Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009640 blood culture Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940047766 co-trimoxazole Drugs 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960000308 fosfomycin Drugs 0.000 description 1
- YMDXZJFXQJVXBF-STHAYSLISA-N fosfomycin Chemical compound C[C@@H]1O[C@@H]1P(O)(O)=O YMDXZJFXQJVXBF-STHAYSLISA-N 0.000 description 1
- 238000002013 hydrophilic interaction chromatography Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229960000564 nitrofurantoin Drugs 0.000 description 1
- NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical group 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- HLBBKKJFGFRGMU-UHFFFAOYSA-M sodium formate Chemical compound [Na+].[O-]C=O HLBBKKJFGFRGMU-UHFFFAOYSA-M 0.000 description 1
- 235000019254 sodium formate Nutrition 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 238000005353 urine analysis Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/493—Physical analysis of biological material of liquid biological material urine
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/72—Mass spectrometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
- G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
- G01N2030/884—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample organic compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/348—Urinary tract infections
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/26—Conditioning of the fluid carrier; Flow patterns
- G01N30/38—Flow patterns
- G01N30/46—Flow patterns using more than one column
- G01N30/466—Flow patterns using more than one column with separation columns in parallel
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/72—Mass spectrometers
- G01N30/7233—Mass spectrometers interfaced to liquid or supercritical fluid chromatograph
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- This invention relates to methods for detecting urinary tract infections (UTls).
- the invention also relates to clinical sample analysis using liquid chromatography.
- UTIs urinary tract infections
- organisms from the Enterobacteriaceae family including one or more of the following microorganisms: Escherichia coli (EC); Klebsiella species such as Klebsiella pneumoniae (KP) or Klebsiella oxytoca (KO); Proteus mirabillis (PM); Enterobacter species (Esp); and Citrobacter species (Csp) (hereinafter common UTI-causing microorganisms).
- Escherichia coli EC
- Klebsiella species such as Klebsiella pneumoniae (KP) or Klebsiella oxytoca (KO)
- PM Proteus mirabillis
- Esp Enterobacter species
- Csp Citrobacter species
- Urinary tract infections are very common and affect over half of women during their lifetime. As a result, urine culture is one of the most common tests done in microbiology.
- Current UTI diagnostic procedures require bacterial culturing steps, which contribute to long diagnostic timelines. Using the current techniques, it takes approximately two days to identify a UTI-causing organism and characterize its antibiotic susceptibility profile.
- UTI urinary tract infections
- a method has been invented for analyzing a urine sample to determine if it contains a microorganism linked to a urinary tract infection.
- a urine sample can be analyzed to determine if it contains at least one decarboxylated amino acid metabolite selected from agmatine, putrescine or cadaverine.
- the presence of agmatine, putrescine or cadaverine in urine is indicative of a urinary tract infection caused by any of the common UTI-causing microorganisms.
- the presence of agmatine is strongly indicative of a urinary tract infection caused by any of the common UTI-causing microorganisms.
- a method of diagnosing a urinary tract infection (UTI) in a patient according to claim 1.
- a non-claimed method for sample analysis, for or apart from UTI issues has also been invented.
- the method offers rapid analysis of complex samples such as body fluids for example urine samples in the case of UTIs and blood samples in the case of blood stream infections.
- the method employs liquid chromatography and mass spectroscopy analysis of chemical substances, in which samples are injected into the liquid chromatography system in a consecutive series of sample plugs under conditions where the target substance(s) will elute under isocratic continuous conditions.
- the method employs a multistage isocratic continuous elution, with continuous, serial injections in one stage and rapid elution from the column in a second stage.
- analogues of metabolites such as adducts, isotopomers, fragments, multiple charge states, etc.
- a metabolite signal in spectrometric analysis may be complex and in fact may include more than one signal per molecule. Overall, the group of signals for that molecule can be resolved and considered a single metabolite signal. For example, a mass spectrometer will detect 10-50 signals for each molecule including the original molecule (parent) plus a variety of analogues of the original molecule including fragments, adducts (chemical combinations that happen in the instrument), multiple charge states and isotopomers (naturally occurring forms of the molecule with 1 or more extra neutrons).
- any of these signals can indicate one molecule, and in this application, any of the analogues of agmatine, putrescine or cadaverine are encompassed as the metabolite of interest: agmatine, putrescine or cadaverine.
- the Enterobacteriaceae family of microbes includes Escherichia coli, Proteus mirabilis, Citrobacter species including Citrobacter braakii , Citrobacter freundii, Citrobacter amalonaticus, Citrobacter farmeri and Citrobacter koseri , Enterobacter species including Enterobacter aerogenes (now classified as Klebsiella aerogenes) and Enterobacter cloacae cplx ., Klebsiella species including Klebsiella oxytoca and or Klebsiella pneumoniae.
- the infection can be identified by analyzing the patient's urine sample for a concentration of one or more of agmatine, putrescine or cadaverine.
- a threshold of 170 nM agmatine or greater in the urine is indicative of an Enterobacteriaceae infection.
- Agmatine was reliably identified in samples from patients suffering from an infection of at least one of Escherichia coli, Proteus mirabilis, Citrobacter species including Citrobacter braakii , Citrobacter freundii, Citrobacter amalonaticus, Citrobacter farmeri and Citrobacter koseri , Enterobacter species including Enterobacter aerogenes and Enterobacter cloacae cplx., Klebsiella species including Klebsiella oxytoca and Klebsiella pneumoniae.
- urine samples from human subjects were analyzed and those samples from subjects infected with Escherichia coli (EC), Proteus mirabilis (PM), Citrobacter species (Csp) including Citrobacter braakii , Citrobacter freundii, Citrobacter amalonaticus, Citrobacter farmeri and Citrobacter koseri , Enterobacter species (Esp) including Enterobacter aerogenes and Enterobacter cloacae cplx .
- Klebsiella species including Klebsiella oxytoca (KO) and Klebsiella pneumoniae (KP) contained agmatine and those samples from subjects not suffering from any UTI (i.e.
- a test for agmatine in the urine can be employed to reliably indicate that a patient is suffering from an infection by any one of the common UTI-causing microorganisms.
- Putrescine ( Figure 6 ) and cadaverine can also be used as indicators, in some cases, to diagnose a UTI in a human subject.
- Enterobacteriaceae such as Escherichia coli, Proteus mirabilis, Citrobacter species, Enterobacter species, and Klebsiella species produce agmatine, and sometimes putrescine or cadaverine, but the human body does not produce any of agmatine, putrescine or cadaverine in the urinary tract.
- Agmatine, putrescine and cadaverine are produced by the breakdown of protein, specifically amino acids. Agmatine is an aminoguanidine created by decarboxylation from the chemical arginine. Putrescine, or tetramethylenediamine, is a metabolite of ornithine or agmatine.
- Cadaverine is also known by the name pentamethylenediamine and is created by decarboxylation of the chemical lysine.
- a method for determining if a patient has a urinary tract infection may include: analyzing a urine sample from the patient for the presence of agmatine, a positive result indicating that the patient has a urinary tract infection resulting from at least one of Escherichia coli; Klebsiella pneumoniae; Klebsiella oxytoca; Proteus mirabillis; Enterobacter species; or Citrobacter species. Because the analysis detects a microorganism metabolite rather than a microorganism directly, sample handling is simplified, for example, the sample can be used without any culturing and, thus, the materials and the time required for culturing are avoided.
- the urine sample from the patient may be analyzed directly after collection.
- the sample may not need to be cultured and therefore a culture-independent sample may be used and a culture-independent analysis can be performed.
- the urine sample may be tested immediately by this method.
- the human urine sample may be preserved using a preservative, for example a buffered borate solution, which prevents any microorganisms therein from growing.
- the urine sample, after collection may be fixed to stop microbial activity with a fixing agent, for example, methanol.
- Human urine sample preparation may also include removing solids, as by for example filtration or centrifuge. Thereafter, the liquid portion, for example the supernatant in the case of centrifugation, of the urine sample is analyzed for the presence of agmatine, putrescine or cadaverine.
- the sample can be enriched using solid phase extraction after fixing and solids removal.
- Solid phase extraction is used to purify biological samples.
- a stationary phase for example, silica, along with a high pH mobile phase is used to capture molecules in the urine sample. The stationary phase then elutes molecules when the pH of the mobile phase is lowered, resulting in purification of the biological sample.
- a method for solid phase extraction is contained in Example 8.
- sample analysis gives a positive result for at least one of agmatine, putrescine or cadaverine, thereby indicating that the patient has a urinary tract infection
- the sample can be further analyzed, if desired, to determine more about the cause of the UTI.
- the urine sample can be tested for antibiotic resistance to determine the appropriate antibiotic that could be used to treat the UTI ( Figure 10 ).
- a metabolic preference assay may be performed to determine the class of antibiotics that could be excluded from treatment of the UTI due to antibiotic resistance.
- the metabolic assay may also indicate the type of pathogen present, for example, gram negative or positive, genus, species etc. and, therefore, instead of a general antibiotic, a specific, appropriate course of antibiotic treatment may be administered to the patient.
- the metabolic preference assay provides an identification of the cell type in a positive result sample, the assay including: incubating the sample in a growth medium; after incubation, analyzing the incubated growth medium by chemical analysis to determine a level of a metabolite in the incubated growth medium; and identifying the cell type by comparison of the level of the metabolite with reference metabolite profiles and matching the level of metabolite with a reference metabolite profile indicative of the cell type.
- the cell type of the organism may be the general class of the organism (i.e. gram negative, gram positive, etc.), the genus or species of origin (i.e. the bacterial species, etc.), or the strain or distinguishing characteristics (i.e. resistance or sensitivity to an antibiotic).
- the growth medium in which cells are grown provides nutrients and accumulates waste products, referred to as metabolites of the microorganism.
- the metabolic signal of microorganisms is amplified over time through cumulative changes in growth medium composition. The incubation period allows cells in the positive result sample to metabolize by consuming their preferred nutrient(s) and secreting waste products.
- Nutrients present in the medium are noted and metabolites after analysis are analyzed to obtain metabolic data for the organisms in the growth medium.
- Reference metabolite profiles which are the known metabolite results for groups of microorganisms or individual species, subspecies or strains, are compared to the metabolic data acquired from analysis of the sample to classify the unknown organism. This method is described in more detail in WO 2018/165751, published September 20, 2018 by the present applicant and incorporated herein by reference.
- agmatine, putrescine or cadaverine are detected in the urine sample, a more specific antibiotic can be administered to the patient such as ampicillin.
- Other possible treatments include ceptra, cephalosporins, nitrofurantoin, fosfomycin, and fluoroquinolones.
- rapid testing could reduce the need for broader spectrum agents such as fluoroquinolones or broad-spectrum cephalosporins.
- additional antibiotic sensitivity testing and/or metabolic preference assay for the actual cell type within the Enterobacteriacaea family may permit a more refined and targeted selection of the antibiotic.
- Analyzing a urine sample from the patient for the presence of agmatine, putrescine or cadaverine may be achieved by various technologies.
- Spectrometric analysis technologies may be used.
- sample separation such as by chromatographic separation may be employed ahead of spectrometric analysis.
- detectors can be used to detect agmatine, putrescine or cadaverine in a urine sample from a patient.
- useful detectors include a mass spectrometer, a UV-Vis spectrophotometric detector, arrayed diode detector, or nuclear magnetic resonance spectrometer.
- urine samples may be analyzed without separation such as chromatography, for example, using a direct injection strategy for example in combination with isotope dilution.
- This strategy is sometimes employed in cases where the target analyte has been purified from the urine sample or when ion suppression effects are controlled via isotope dilution.
- One current practice is to analyze samples via direct injection techniques that couple the auto sampler directly to a mass analyzer and thereby omit the chromatographic separation step. This direct injection strategy circumvents the time required for chromatographic approaches, but is only quantitatively robust when analyzing low-complexity solutions.
- SPE Solid Phase Extraction
- LC liquid chromatography
- solvent the mobile phase
- the invention provides increasing the sample throughput by shortening the run time for sample detection by serially injecting a plurality of samples into a continuous flow of solvent through an LC system. This is known as isocratic chromatography.
- samples may be analysed using mobile-phase chromatographic solvents that are maintained at a substantially constant composition over time ( Figure 2B ).
- Figure 2B mobile-phase chromatographic solvents that are maintained at a substantially constant composition over time
- the composition of the mobile phase is selected to enable a moderate exchange rate between bound and unbound states of the analyte.
- the constant composition of the solvent allows for the preferential retention of the target analyte.
- Isocratic continuous elution is surprisingly useful for identifying the presence of the target compounds and analyzing complex biological samples, for example urine samples.
- Isocratic continuous LC allows sample-to-sample intervals of about 1 minute. The time interval between samples is affected by the column physical dimensions, the flow rate of the solvent, the chemical properties of the solvent, the chemical composition of the column stationary phase, the temperature of the column, the fluid pressure within the column, and the operational capabilities of the auto sampler (for example, the rate at which the instrumentation can perform repeat injections). Under typical analytical conditions, the time interval between eluting peaks from the target analytes will range from 30 to 90 seconds. This is a fraction of the time required for conventional gradient chromatography, as shown by comparison of Figures 3A and 3B .
- LC liquid chromatography
- MS mass spectrometry
- an inherent problem encountered when analyzing complex samples by LC-MS is that there may be differential ion suppression where different compounds, such as salt forms, elute from the column at different rates into the detector.
- Differential ion suppression refers to signal variation as a result of competition for ionization of analytes within the ion source. Differential ion suppression causes even the exact same sample to show up at different intensities when injected multiple times thereby limiting the accuracy and precision of LC-MS.
- isocratic continuous chromatographic elution is combined with a method in which a known concentration of an isotope-labeled version of the target analyte is added to each sample and concentrations of the target analyte are calculated from the observed ratio of 12 C/ 13 C signals.
- This isotope normalization strategy also called isotope dilution, corrects for errors resulting from differential ion suppression because the target analyte and isotope-labeled target analyte co-elute and are thereby subjected to the same ionization and chromatographic conditions.
- Figure 4 shows quantification of known concentrations of 12 C agmatine using this isotope normalization method and demonstrates that robust quantification of target analyte levels can be achieved across a wide range of concentration values, including clinically relevant concentration values.
- the quantitative performance of the method was assessed using a panel of healthy urine samples that were spiked with a range of 12 C agmatine standards and 100 nM U- 13 C agmatine as an internal reference. Injected samples were analysed by a column running isocratically and concentrations were calculated using a calibration curve shown in Figure 5 . The quantitative performance was assessed using an independent set of quality control samples.
- Analysis of a urine sample can be spiked with a known concentration of an isotope of the target analyte, which in the case of the present method for detecting UTIs is one or more of agmatine, putrescine or cadaverine, and the signal intensity for the known concentration of isotope labelled target analyte can be employed to normalize quantitative variability and calculate the concentration of the target analyte.
- This method includes detecting both the target analyte and the simultaneously eluting isotope-labelled version of the target analyte and comparing their peak intensities. Using isocratic continuous elution and isotope dilution, the samples can be accurately analysed despite variability in ion suppression. This isotope dilution strategy enables target analytes to be accurately quantified in a plurality of urine samples injected sequentially into a continuous isocratic gradient.
- chromatographic separation of analytes may include a two-stage, isocratic continuous elution to achieve good separation and close spacing of chromatographic peaks.
- This methodology is illustrated in Figure 2C .
- the two-stage isocratic continuous chromatography method comprises: in the first stage, a first mobile phase is used to inject a plurality of samples onto the column followed by a second stage, where a second mobile phase is used to elute analytes off the column for analyte detection such as by MS.
- the second mobile phase has a composition different from the first mobile phase.
- the mobile phases may differ in hydrophobicity, solvent ionic strength, solvent composition, pH, etc.
- the first mobile phase differs from the second mobile phase in terms of its hydrophobicity, where the first mobile phase is more hydrophobic than the second mobile phase.
- the first mobile phase is selected to provide a slow elution of the target analyte off the LC column.
- Two-stage isocratic chromatography enables analysis of target analytes from a plurality of samples by enabling multiple samples to be loaded onto a column in the first stage, then rapidly eluted during the second stage.
- the elution of all the samples in the second stage can occur in less, sometimes much less, time than the time taken for the sample injections in the first stage.
- the first mobile phase is selected for the target analyte to allow moderate binding of the analyte onto the column stationary phase such that analytes from a plurality of samples migrate through the column in a progressive series of peaks.
- the second mobile phase is selected to elute samples off the column rapidly, but substantially maintain the binding of non-target analytes.
- This two-stage strategy separates the target molecule in a plurality of samples while minimizing the amount of time necessary clear the column of target analytes.
- the second mobile phase enables analytes from a consecutive series of samples to be eluted in a much shorter time than is possible from a single stage of chromatography. Consequently, quantitative analysis of a series of samples loaded onto a column may be completed in a fraction of the time necessary to load the samples.
- the two-stage isocratic continuous chromatography method can further include a multiplexed column injection schedule where a plurality of columns are employed ( Figures 1 and 2D ). Each column can accept a number of samples that can be sequentially loaded until the column reaches its carrying capacity. This capacity is dictated by the physical and chemical properties of the column (e.g. 12 samples for the column used for Figure 8 ). Any potential timesavings through two-stage isocratic chromatography are restricted to analyses of samples in batches equal to or smaller than the carrying capacity of the column.
- multiplexing a plurality of columns allows timesavings to be extended to greater numbers of samples by sequentially loading, then eluting, target analytes off of a series of columns.
- an apparatus enabling loading of multiple columns while simultaneously eluting another column could enable continuous analysis of large numbers of samples.
- a LC system may including two or more columns 10a, 10b, configured to connect to the same detector, such as a mass spectrometer 12.
- This provides serial elution of samples off the plurality of columns 10a, 10b resulting in a substantially steady and high frequency flow of analytes entering the mass spectrometer for detection and analysis ( Figure 3C ).
- the columns may receive samples from the same source, for example, an auto-sampler 14 with samples a first mobile phase (dashed line). Both columns 10a, 10b may also receive a second mobile phase (dotted line) from another source, for example an elution pump 16.
- a valve switch 18a may be used to switch communication between the sampler and each of the two columns while communication is also switched between the elution pump and the two columns.
- Another valve switch 18b may be provided at the output ends of the columns alternate communication of the detector to each of the first and second columns in turn.
- the valve switch directs eluting phases appropriately to either the mass spectrometer 12 or to waste 20.
- the mobile phase coming off the column may be directed to waste during re-conditioning/equilibrium stages and any time the eluting mobile phase does not need to be analyzed by the detector. If a further mobile phase is required for reconditioning, a further supply may be added to and upstream of the valve switch 18a,
- first column 10a may be injected with multiple samples using the first mobile phase, while a second column may elute analytes from the sample using a second mobile phase. Blocks of samples are injected on each column at different times.
- the basic premise of this aspect of the method is that a series of samples are injected onto the first column and then samples are eluted off the second column, where the injection and elution occurs in an alternating or sequential fashion on separate columns.
- the first column is in the first stage while the second column is in the second stage. This process is cycled, while one column elutes samples into the mass spectrometer, the other re-equilibrates and is loaded up with samples, for example by an auto-sampler.
- analysing includes a two-stage, isocratic continuous elution and a multiplexed column injection schedule. This achieves high sample throughput and good use of laboratory time and resources on an LC-MS platform for targeted compound detection in complex samples.
- valve switch 18a may be used to switch the mobile phase being run on a column rapidly between two mobile phases: first mobile phase (dashed line) having a composition selected to be suitable for injection of samples, as from the auto-sampler; and second mobile phase (dotted line) configured to rapidly elute the target compound from the column, as from elution pump 16.
- first mobile phase dashed line
- second mobile phase dotted line
- State A shows Column 1 in the first stage and Column 2 in the second stage
- State B which has been switched over by the valve switch 18a, shows Column 1 is in the second stage and Column 2 in first stage.
- Valve switch 18b at the eluted end of the columns alternately communicates eluted analytes from the two columns one at a time to the mass spectrometer. While two columns are shown in Figure 1 , it is to be understood that this method can employ more than two columns.
- isocratic continuous chromatography is used to detect the presence of at least one decarboxylated amino acid metabolite selected from agmatine, putrescine or cadaverine for diagnosing a patient suffering from a UTI, wherein culture-independent urine sample from the patient is analyzed by isocratic continuous chromatography.
- two-stage, isocratic continuous chromatography is used to detect the presence at least one decarboxylated amino acid metabolite selected from agmatine, putrescine or cadaverine for use in diagnosing a patient suffering from a UTI, wherein culture-independent urine samples from the patient is analyzed by two-stage, isocratic continuous chromatography.
- a multiplexed column injection schedule where a plurality of columns are employed and a two-stage, isocratic continuous chromatography is used to detect the presence at least one decarboxylated amino acid metabolite selected from agmatine, putrescine or cadaverine for use in diagnosing a patient suffering from a UTI, wherein culture-independent urine sample from the patients is analyzed by two-stage, isocratic continuous chromatography.
- analyzing a urine sample from the patient is achieved using LC-MS focusing on detection of agmatine.
- Agmatine has shown the highest level of ionization and highest predictive capacity relative to putrescine and cadaverine.
- a method for continuous isocratic chromatography was initially optimized using simulated UTI samples constructed from an unlabeled agmatine standard spiked into a healthy urine control sample.
- Optimal isocratic solvent composition for agmatine was determined to be 86% acetonitrile with 0.1% (v/v) formic acid, which allowed for high binding while still maintaining mobility of agmatine on the column to allow for quick plug spacing.
- An offset between binding and elution of about 4% was deemed beneficial to improve the chromatographic peak shape while expediting column elution and maintaining baseline separation between sample peaks, as shown in Figure 3B .
- These conditions enabled serial injection with as little as 30 second spacing between peaks.
- urine samples were injected with isotope-labelled 13 C agmatine.
- Example IB Analysis of isotope diluted, two-stage, isocratic continuous elution and with a multiplexed column injection
- Urine samples were spiked with 13 C agmatine and analyzed on a Thermo Q-Exactive TM HF LC-MS platform using a Syncronis TM HILIC column.
- a binary solvent system comprising 20 mM ammonium formate pH 3.00 (solvent A) and acetonitrile with 0.1% (v/v) formic acid (solvent B) was employed for chromatographic separation. Mass spectra were collected in positive ion mode using parallel reaction monitoring.
- Isotope diluted, two-stage, isocratic continuous elution with a multiplexed column injection schedule analyses were conducted by i) serially injecting isotope-tagged urine samples in a continuous 86% solvent B (first mobile phase) isocratic flow and ii) eluting the serial sample plugs using an isocratic step at 82% solvent B (second mobile phase).
- Hardware including a switch valve ( Figure 1 ) ensured that step i) was conducted in the first column while step ii) was conducted in the second column and that the solvent was immediately changed when changing the elution from first mobile phase to second mobile phase and back to the first mobile phase, in an alternating fashion.
- Differential ion suppression was controlled by quantifying the isotope ratio between native agmatine metabolites versus the coeluting 13 C standards.
- a sample of urine spiked with 5 uM 12 C and 500 nm U- 13 C agmatine is injected 12 times in a row using isocratic continuous chromatography. Note how the signal errors (illustrated by signal to signal variance) for both the target compound, specifically agmatine and the isotope-labelled agmatine are the same for each sample.
- computing the concentration of the 12 C analyte from the observed ratio of 12 C versus 13 C signals cancels out error term, for example differential ion suppression, which may be caused by variations in ionization or chromatography sample-to-sample.
- This method enables the concentrations of analytes to be accurately determined despite significant sample-to-sample and column-to-column variability in the performance of the detection system.
- peaks detected representing the nine urine samples and three blocks of peaks eluting over time, representing three technical replications that were performed demonstrating the stability and reliability of the method.
- the microbial culture example used here illustrates the general applicability of the method for microbial analyses.
- the microbial culture conditions used for this study are similar to those used in analysis of bloodstream infections (BSIs) and thereby indicate the applicability of the method to other clinical applications, including detection of BSIs.
- BSIs bloodstream infections
- Example IA namely isotope-labelled, isocratic continuous chromatography
- Example IB namely isotope-labelled, two-stage, isocratic continuous chromatography with a multiplexed column injection schedule
- FIG. 7 and 8 shows the detection of isotope labelling of 13 C agmatine
- the upper left chart of Figures 7 and 8 shows ninety-six urine samples which tested negative for a UTI
- the upper right chart of Figures 7 and 8 shows ninety-six urine samples which tested positive for Escherichia coli.
- FIG 7 the samples were analyzed by isocratic continuous chromatography according to the methodology described in Example IA and in Figure 8 , the samples were analyzed by two-stage, isocratic continuous chromatography with a multiplexed column injection schedule according to the methodology described in Example IB.
- Figures 7 and 8 show negative urine samples (no infection by UTI-causing microorganisms) on the upper left hand chart and Escherichia coli -infected urine samples on the upper right hand chart.
- a blinded cohort of urine samples from patients were subjected to two-stage, isocratic continuous chromatography with a multiplexed column injection schedule to detect native agmatine content.
- the patient urine samples were separately analyzed via traditional UTI diagnostic methods. Using only agmatine, the data suggests that agmatine presence in uncultured or culture-independent urine samples can diagnose roughly 85% of patients that present clinically with a bacterial urinary tract infection.
- 192 patient samples were submitted to multicolumn, two-stage and isocratic continuous chromatography analysis as in Example IB.
- the overall run time was 430 minutes, which included 192 patient samples with two technical replicates and a number of quality control blank injections providing 448 total injections. This averages out to an average run time of 1.1 minutes per patient sample overall and 0.96 minutes per injection.
- the false positive was likely a product of differences between the internal positivity threshold and that of the traditional microbiology assay. All false negatives were expected, coming from microbes that are not known to produce agmatine in urine. Overall this is an extremely fast and effective screen compared to conventional detection methodologies that if implemented would have a significant impact on the speed of diagnosis of UTIs as well as circumvent the need to culture 85% of patient samples. Only the negative samples would have to be cultured for confirmation of bacterial UTI.
- Urine samples are typically collected in urine culture tubes containing a buffered boric acid solution that minimizes microbial growth during sample transport to the microbiology laboratory.
- MG1665, ATCC 25922, ESBL ATCC BAA-196, and 4 clinical isolates were seeded in Mueller Hinton medium overnight, and subcultured in filter-sterilized urine with or without preservatives (boric acid, 2.63mg/mL; sodium borate, 3.95mg/mL; sodium formate, 1.65mg/mL).
- a cohort of Escherichia coli positive urine samples with a diverse range of susceptibility profiles were analyzed by metabolic preference assay. Bacteria from these samples were pelleted, washed, and re-suspended in equal volumes of Mueller Hinton medium. 96-well plates were seeded with 10% of the washed cells, were incubated for four hours in the presence or absence of clinically relevant concentrations of antibiotics, and were analyzed by LC-MS ( Figure 10 ). Metabolic preference assay based diagnostics closely recapitulated the antibiotic susceptibility profiles reported via the traditional culture-based approach. There was substantial agreement between the breakpoints determined by metabolic preference assay based and traditional culture-based approaches for the antibiotics. The metabolic preference assay strategy correctly assigned antibiotic susceptibilities in 97% of samples.
- Example 7 Agmatine as an indicator of a UTI
- the data set included a limited number of these organisms, none of which produced detectable levels of agmatine.
- a diagnostic agmatine threshold of about 0.17 ⁇ M for differentiating culture-negative versus culture-positive samples was calculated. This threshold was calibrated to correspond to about 97% specificity and 94% sensitivity for the detection of Enterobacteriaceae-linked UTIs.
- Example 8 Solid phase extraction (SPE) of agmatine from urine samples
- Urine samples in 50% methanol (1.2 mL) were centrifuged at 14,800g for five minutes. From these samples, 800 ⁇ L of urine was added to 200 ⁇ L isotope-dilution solution of 1 ⁇ M [U-13C] agmatine and 100 mM ammonium bicarbonate (pH 8.0) in 50% methanol for a final concentration of 200 nM [U-13C] agmatine and 20 mM ammonium bicarbonate.
- Thermo Scientific HyperSep Silica 96-well plates (25 mg bed volume, 1 mL column capacity) were pre-equilibrated with 400 ⁇ L HPLC-grade methanol followed by 400 ⁇ L 50% HPLC-grade methanol/H2O.
- the 1 mL prepared sample was added to the column and allowed to drip through.
- a methanol wash was conducted with 1 mL HPLC methanol followed by a water wash with 1 mL HPLC water. All of the solutions used in the washing steps were assisted through the columns by centrifugal force (20g for 5 min).
- the column was then primed by adding 250 ⁇ L of 99.9% methanol with 0.1% formic acid.
- 125 ⁇ L H2O with 2% formic acid was allowed to drip through the column.
- the first set of 196 samples contained a 13C agmatine concentration of 100 nM and a final volume of 500 ⁇ L.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Description
- This invention relates to methods for detecting urinary tract infections (UTls). The invention also relates to clinical sample analysis using liquid chromatography.
- More than 75% of urinary tract infections (UTIs) are caused by organisms from the Enterobacteriaceae family including one or more of the following microorganisms: Escherichia coli (EC); Klebsiella species such as Klebsiella pneumoniae (KP) or Klebsiella oxytoca (KO); Proteus mirabillis (PM); Enterobacter species (Esp); and Citrobacter species (Csp) (hereinafter common UTI-causing microorganisms).
- Urinary tract infections (UTIs) are very common and affect over half of women during their lifetime. As a result, urine culture is one of the most common tests done in microbiology. Current UTI diagnostic procedures require bacterial culturing steps, which contribute to long diagnostic timelines. Using the current techniques, it takes approximately two days to identify a UTI-causing organism and characterize its antibiotic susceptibility profile.
- Under ideal circumstances, the organism(s) causing a UTI would be identified and their antibiotic susceptibility would be measured before antibiotics were prescribed to ensure proper infection management. However, the long timelines required for UTI diagnosis make it impractical to wait for clinical results. Consequently, many patients are given antibiotic therapy that is not properly matched to their condition. A faster diagnostic method would reduce complications from improperly treated UTIs.
- Methods have been invented for detecting urinary tract infections (UTI).
- A method has been invented for analyzing a urine sample to determine if it contains a microorganism linked to a urinary tract infection. A urine sample can be analyzed to determine if it contains at least one decarboxylated amino acid metabolite selected from agmatine, putrescine or cadaverine. The presence of agmatine, putrescine or cadaverine in urine is indicative of a urinary tract infection caused by any of the common UTI-causing microorganisms. The presence of agmatine is strongly indicative of a urinary tract infection caused by any of the common UTI-causing microorganisms.
- Thus, in accordance with the invention, there is provided a method of diagnosing a urinary tract infection (UTI) in a patient according to
claim 1. - While urine samples can be analyzed by various methods for at least one of agmatine, putrescine or cadaverine, a method for rapid sample analysis is of great value since a laboratory may have many hundreds of samples to analyze every day due to the frequency of UTIs. Thus, a non-claimed method for sample analysis, for or apart from UTI issues, has also been invented. The method offers rapid analysis of complex samples such as body fluids for example urine samples in the case of UTIs and blood samples in the case of blood stream infections. The method employs liquid chromatography and mass spectroscopy analysis of chemical substances, in which samples are injected into the liquid chromatography system in a consecutive series of sample plugs under conditions where the target substance(s) will elute under isocratic continuous conditions. In another embodiment, the method employs a multistage isocratic continuous elution, with continuous, serial injections in one stage and rapid elution from the column in a second stage.
- It is to be understood that other aspects of the present invention will become readily apparent to those skilled in the art from the following detailed description, wherein various embodiments of the invention are shown and described by way of example. As will be realized, the invention is capable for other and different embodiments and several details of its design and implementation are capable of modification in various other respects, all captured by the present claims. Accordingly, the detailed description and examples are to be regarded as illustrative in nature and not as restrictive.
- For a better appreciation of the invention, the following Figures are appended:
-
Figure 1 is a schematic diagram of the two-stage isocratic continuous chromatography set up with a multiplexed column injection schedule where two columns were employed. -
Figures 2A to 2D are schematic diagrams of the timing scenarios of LC analysis (TO) for multiple sample injections (TI) for four different chromatographic methods: a conventional 3 minute gradient (Figure 2A ); isocratic continuous chromatography (Figure 2B ); two stage isocratic continuous chromatography (Figure 2C ); and multiplexed, two stage isocratic continuous chromatography, where there are two columns each operating in a two-stage, isocratic continuous chromatographic method (Figure 2D ). The isocratic continuous chromatography (Figure 2B ) includes a time Tl of repeated sample injections (arrows), followed by sample elute detection TD using an isocratic solvent and possibly followed by a column reconditioning TR using a selected mobile phase to clear the column. The two stage isocratic continuous chromatography (Figure 2C ) includes a first stage, including sample injection TI using Solvent 8 (i.e. a first mobile phase) and a second stage, including sample elution using a solvent different than solvent B (i.e. a second mobile phase) for during which the separated molecules elute as peaks and are detected TD, possibly followed by a column reconditioning stage TR using a selected mobile phase to clear the column. The multiplexed, two stage isocratic continuous chromatography (Figure 2D ) includes two columns, where whenColumn 1 is in the second stage TD and TR,Column 2 is in the first stage TI and the column stages alternate - such that more samples can be analyzed over time and more effective utilization of the detector can be achieved. -
Figures 3A to 3C are comparisons of sample peaks eluted per laboratory unit time: from a conventional 3 minute gradient (Figure 3A ), isocratic continuous chromatography (Figure 3B ), and two-stage, isocratic continuous chromatography (Figure 3C ). The eluted samples arise from repeated injection of a sample of urine containing 5 uM of an agmatine standard. -
Figure 4 is a representation of the error effect caused by differential ion suppression during isocratic continuous chromatography sample runs (upper chart) and isocratic continuous chromatography sample runs using isotope-labelled agmatine C13 (lower chart), which shows that the ratio of agmatine to isotope-labelled agmatine can be employed to correct the error. -
Figure 5 shows two graphs demonstrating that accurate measurement of agmatine can be achieved by isotope-labelled agmatine over clinically relevant agmatine concentrations using isocratic continuous chromatography, isotope-labeled agmatine is added as an internal reference for each sample and concentrations are calculated by ratio of agmatine to isotope-labelled agmatine. The upper chart shows a calibration curve of 12C agmatine standards added to urine samples containing 100 nM 13C agmatine. The lower chart shows independent quality-control urine samples with a known amount of 12C agmatine versus the agmatine concentrations calculated based on the observed isotopic ratio. -
Figure 6 is a comparison of the levels of 12C and 13C putrescine in nine Escherichia coli cultures and nine Pseudomonas aeruginosa cultures analyzed by isocratic continuous chromatography (3 technical replicates). The culture methods used to generate these samples are compatible with the established methods for detecting bloodstream infections. -
Figure 7 is a comparison of the levels of 12C and 13C agmatine levels in ninety-six human urine samples that tested negative for bacterial growth using isocratic continuous chromatography (upper left chart) versus ninety-six human urine samples that tested positive for Escherichia coli infection using isocratic continuous chromatography (upper right chart). Concentrations of 12C agmatine were calculated from the ratio of 12C/13C multiplied by the known concentration of the 13C agmatine standard (lower chart showing isotopically labelled agmatine standard). -
Figure 8 is a comparison of the levels of 12C and 13C agmatine of ninety-six human urine samples that tested negative for bacterial growth using two-stage, isocratic continuous chromatography with a multiplexed column injection schedule where two columns were employed (upper left chart) versus ninety-six human urine samples that tested positive for Escherichia coli infection using two-stage, isocratic continuous chromatography with a multiplexed column injection schedule where two columns were employed (upper right chart). Concentrations of 12C agmatine were calculated from the ratio of 12C/13C multiplied by the known concentration of the 13C agmatine standard (lower chart showing isotopically labelled agmatine standard). -
Figure 9 is a plot showing agmatine concentrations observed in urine samples from healthy patients (Neg) and patients with urinary tract infections caused by six different types of bacteria - Escherichia coli (EC); Klebsiella species such as Klebsiella pneumoniae (KP) or Klebsiella oxytoca (KO); Proteus mirabillis (PM); Enterobacter species (Esp); and Citrobacter species (Csp). The upper block represents agmatine concentrations observed in the sample while the lower block shows the same data on a log10 scale. Dotted lines in the second block indicate a threshold at 58 nM, which was determined by isotope ratio and corresponds to UTI detection threshold associated with a sensitivity of 0.94 and specificity of 0.99. -
Figure 10 is a schematic showing a metabolic preference assay (MPA) for determining the susceptibility of eight clinical E.coli isolates (rows I1-I8) to four antibiotics at a range of concentrations. Metabolic activity was monitored via succinate levels, a metabolite secreted by Escherichia coli in culture. Increased metabolite production relative to control medium (light grey) is indicative of metabolic activity characteristic of resistance to a given concentration of antibiotic. A decrease in metabolite production relative to control (dark grey) is indicative of antibiotic sensitivity. Three technical replicates were performed for each isolate, under each condition. Black bars are indicative of the antibiotic sensitivity profiles of each isolate, as determined by traditional culture based approach at a regional diagnostic laboratory (CLS). Concentrations are in µg/mL. Where T/S refers to trimethoprimsulfamethoxazole. -
Figure 11 is a schematic showing agmatine may be used as an indicator for the presence of a UTI. Five hundred and nineteen samples were obtained from Alberta Public Laboratories and analyzed. Agmatine concentrations were tightly linked to culture positive samples containing Enterobacteriaceae. The samples were split in the schematic into subgroups based on speciation results. - The detailed description and examples set forth below are intended as a description of various embodiments of the present invention and are not intended to represent the only embodiments contemplated by the inventor. The detailed description includes specific details for the purpose of providing a comprehensive understanding of the present invention. However, it will be apparent to those skilled in the art that the present invention may be practiced without these specific details.
- Analysis of urine samples from humans indicated that suprisingly agmatine, putrescine or cadaverine were present in the urine samples at elevated levels in at least 75% of urinary tract infections (UTI) while this was not true of urine samples from healthy patients. The study showed that urine from human subjects without a UTI had agmatine, putrescine or cadaverine concentrations that were not detectable given the detection limits of the assay (50 nM).
- As will be appreciated, analogues of metabolites, such as adducts, isotopomers, fragments, multiple charge states, etc., are also considered to be the metabolite. It is noted that a metabolite signal in spectrometric analysis may be complex and in fact may include more than one signal per molecule. Overall, the group of signals for that molecule can be resolved and considered a single metabolite signal. For example, a mass spectrometer will detect 10-50 signals for each molecule including the original molecule (parent) plus a variety of analogues of the original molecule including fragments, adducts (chemical combinations that happen in the instrument), multiple charge states and isotopomers (naturally occurring forms of the molecule with 1 or more extra neutrons). Detecting any of these signals can indicate one molecule, and in this application, any of the analogues of agmatine, putrescine or cadaverine are encompassed as the metabolite of interest: agmatine, putrescine or cadaverine.
- The present research surprisingly concluded that UTI's caused by microbes of the Enterobacteriaceae family can be diagnosed by detecting agmatine, putrescine and/or cadaverine in the urine of a patient. The Enterobacteriaceae family of microbes includes Escherichia coli, Proteus mirabilis, Citrobacter species including Citrobacter braakii, Citrobacter freundii, Citrobacter amalonaticus, Citrobacter farmeri and Citrobacter koseri, Enterobacter species including Enterobacter aerogenes (now classified as Klebsiella aerogenes) and Enterobacter cloacae cplx., Klebsiella species including Klebsiella oxytoca and or Klebsiella pneumoniae. All Enterobacteriaceae studied produced agmatine, putrescine and/or cadaverine. Thus, regardless of whether the infection was from Escherichia coli; Klebsiella species; Proteus mirabilis; Enterobacter species; Citrobacter species, the infection can be identified by analyzing the patient's urine sample for a concentration of one or more of agmatine, putrescine or cadaverine. A threshold of 170 nM agmatine or greater in the urine is indicative of an Enterobacteriaceae infection.
- Agmatine was reliably identified in samples from patients suffering from an infection of at least one of Escherichia coli, Proteus mirabilis, Citrobacter species including Citrobacter braakii, Citrobacter freundii, Citrobacter amalonaticus, Citrobacter farmeri and Citrobacter koseri, Enterobacter species including Enterobacter aerogenes and Enterobacter cloacae cplx., Klebsiella species including Klebsiella oxytoca and Klebsiella pneumoniae. With reference to
Figures 9 and11 , for example, urine samples from human subjects were analyzed and those samples from subjects infected with Escherichia coli (EC), Proteus mirabilis (PM), Citrobacter species (Csp) including Citrobacter braakii, Citrobacter freundii, Citrobacter amalonaticus, Citrobacter farmeri and Citrobacter koseri, Enterobacter species (Esp) including Enterobacter aerogenes and Enterobacter cloacae cplx., Klebsiella species including Klebsiella oxytoca (KO) and Klebsiella pneumoniae (KP) contained agmatine and those samples from subjects not suffering from any UTI (i.e. negative for UTI) had undetectable agmatine levels. Thus, surprisingly a test for agmatine in the urine can be employed to reliably indicate that a patient is suffering from an infection by any one of the common UTI-causing microorganisms. Putrescine (Figure 6 ) and cadaverine can also be used as indicators, in some cases, to diagnose a UTI in a human subject. - Enterobacteriaceae such as Escherichia coli, Proteus mirabilis, Citrobacter species, Enterobacter species, and Klebsiella species produce agmatine, and sometimes putrescine or cadaverine, but the human body does not produce any of agmatine, putrescine or cadaverine in the urinary tract. Agmatine, putrescine and cadaverine are produced by the breakdown of protein, specifically amino acids. Agmatine is an aminoguanidine created by decarboxylation from the chemical arginine. Putrescine, or tetramethylenediamine, is a metabolite of ornithine or agmatine. Cadaverine is also known by the name pentamethylenediamine and is created by decarboxylation of the chemical lysine.
- Thus, in one embodiment a method for determining if a patient has a urinary tract infection may include: analyzing a urine sample from the patient for the presence of agmatine, a positive result indicating that the patient has a urinary tract infection resulting from at least one of Escherichia coli; Klebsiella pneumoniae; Klebsiella oxytoca; Proteus mirabillis; Enterobacter species; or Citrobacter species. Because the analysis detects a microorganism metabolite rather than a microorganism directly, sample handling is simplified, for example, the sample can be used without any culturing and, thus, the materials and the time required for culturing are avoided.
- In one embodiment, the urine sample from the patient may be analyzed directly after collection. The sample may not need to be cultured and therefore a culture-independent sample may be used and a culture-independent analysis can be performed.
- After collection, the urine sample may be tested immediately by this method. Alternatively, the human urine sample may be preserved using a preservative, for example a buffered borate solution, which prevents any microorganisms therein from growing. Alternatively, the urine sample, after collection may be fixed to stop microbial activity with a fixing agent, for example, methanol. Human urine sample preparation may also include removing solids, as by for example filtration or centrifuge. Thereafter, the liquid portion, for example the supernatant in the case of centrifugation, of the urine sample is analyzed for the presence of agmatine, putrescine or cadaverine.
- Optionally, the sample can be enriched using solid phase extraction after fixing and solids removal. Solid phase extraction is used to purify biological samples. A stationary phase, for example, silica, along with a high pH mobile phase is used to capture molecules in the urine sample. The stationary phase then elutes molecules when the pH of the mobile phase is lowered, resulting in purification of the biological sample. A method for solid phase extraction is contained in Example 8.
- If sample analysis gives a positive result for at least one of agmatine, putrescine or cadaverine, thereby indicating that the patient has a urinary tract infection, the sample can be further analyzed, if desired, to determine more about the cause of the UTI. For example, the urine sample can be tested for antibiotic resistance to determine the appropriate antibiotic that could be used to treat the UTI (
Figure 10 ). If the sample gives a positive result, a metabolic preference assay may be performed to determine the class of antibiotics that could be excluded from treatment of the UTI due to antibiotic resistance. The metabolic assay may also indicate the type of pathogen present, for example, gram negative or positive, genus, species etc. and, therefore, instead of a general antibiotic, a specific, appropriate course of antibiotic treatment may be administered to the patient. - The metabolic preference assay provides an identification of the cell type in a positive result sample, the assay including: incubating the sample in a growth medium; after incubation, analyzing the incubated growth medium by chemical analysis to determine a level of a metabolite in the incubated growth medium; and identifying the cell type by comparison of the level of the metabolite with reference metabolite profiles and matching the level of metabolite with a reference metabolite profile indicative of the cell type. The cell type of the organism may be the general class of the organism (i.e. gram negative, gram positive, etc.), the genus or species of origin (i.e. the bacterial species, etc.), or the strain or distinguishing characteristics (i.e. resistance or sensitivity to an antibiotic).
- For a metabolic preference assay, the growth medium in which cells are grown provides nutrients and accumulates waste products, referred to as metabolites of the microorganism. The metabolic signal of microorganisms is amplified over time through cumulative changes in growth medium composition. The incubation period allows cells in the positive result sample to metabolize by consuming their preferred nutrient(s) and secreting waste products. Nutrients present in the medium are noted and metabolites after analysis are analyzed to obtain metabolic data for the organisms in the growth medium. Reference metabolite profiles, which are the known metabolite results for groups of microorganisms or individual species, subspecies or strains, are compared to the metabolic data acquired from analysis of the sample to classify the unknown organism. This method is described in more detail in
WO 2018/165751, published September 20, 2018 by the present applicant and incorporated herein by reference. - Due to the present rapid diagnosis, if agmatine, putrescine or cadaverine are detected in the urine sample, a more specific antibiotic can be administered to the patient such as ampicillin. Other possible treatments include ceptra, cephalosporins, nitrofurantoin, fosfomycin, and fluoroquinolones. However, rapid testing could reduce the need for broader spectrum agents such as fluoroquinolones or broad-spectrum cephalosporins. Above noted additional antibiotic sensitivity testing and/or metabolic preference assay, for the actual cell type within the Enterobacteriacaea family may permit a more refined and targeted selection of the antibiotic.
- Analyzing a urine sample from the patient for the presence of agmatine, putrescine or cadaverine may be achieved by various technologies.
- Spectrometric analysis technologies may be used. In some cases, sample separation such as by chromatographic separation may be employed ahead of spectrometric analysis.
- In particular, detectors can be used to detect agmatine, putrescine or cadaverine in a urine sample from a patient. Useful detectors include a mass spectrometer, a UV-Vis spectrophotometric detector, arrayed diode detector, or nuclear magnetic resonance spectrometer.
- These detectors may be employed to accept the sample after separation thereof or, sometimes directly. In particular, in some method, urine samples may be analyzed without separation such as chromatography, for example, using a direct injection strategy for example in combination with isotope dilution. This strategy is sometimes employed in cases where the target analyte has been purified from the urine sample or when ion suppression effects are controlled via isotope dilution. One current practice is to analyze samples via direct injection techniques that couple the auto sampler directly to a mass analyzer and thereby omit the chromatographic separation step. This direct injection strategy circumvents the time required for chromatographic approaches, but is only quantitatively robust when analyzing low-complexity solutions. Since diagnostic applications typically involve analyses of complex samples, current practices may include iterative sample extraction and molecular purification steps, such as Solid Phase Extraction (SPE). These procedures allow complex samples to be analyzed via rapid direct-injection approaches and minimize quantitative errors resulting from ion suppression, but introduce additional sources of experimental error.
- Most commonly, complex samples such as urine are analysed by separation first and then detection. Liquid chromatography (LC) is recognized as a useful approach for analyte separation from complex samples. Conventional liquid chromatography typically uses a gradient of two or more solvents, where after sample injection the type and concentration of solvent is varied over time, to separate the constituent compounds from each sample. Each sample is injected onto the column then eluted using a flow of solvent (the mobile phase), which varies in composition over time as shown in
Figure 2A . Although conventional chromatography is effective, the length of time required to inject a sample, complete a gradient, and allow the column to re-equilibrate is not ideal for analyses where a plurality of samples are to be analyzed in the minimum period of time. With conventional LC, it can be difficult to achieve robust data quality using LC run times shorter than 3 minutes when analyzing complex samples, such as urine (Figure 3 ). While such time frames may be acceptable in some situations, the large number of clinical samples related to UTI that most clinics handle highlights the importance of sample throughput. Complex biological samples typically require extended LC gradients or multi-step extraction protocols to minimize quantitative problems related to ion suppression. However, time intensive methods are undesirable for clinical applications that routinely see hundreds of samples per day. Consequently, clinical LC must balance throughput with quantitative performance. - To increase sample throughput without requiring additional sample purification procedures, it is desirable to shorten the time for chromatographic separation of molecules. In one embodiment, the invention provides increasing the sample throughput by shortening the run time for sample detection by serially injecting a plurality of samples into a continuous flow of solvent through an LC system. This is known as isocratic chromatography. In this embodiment, samples may be analysed using mobile-phase chromatographic solvents that are maintained at a substantially constant composition over time (
Figure 2B ). Thus, a plurality of samples can be injected onto a column without substantially altering the mobile phase solution conditions and without employing a gradient of solvents. To enable separation of the target analyte, the composition of the mobile phase is selected to enable a moderate exchange rate between bound and unbound states of the analyte. The constant composition of the solvent allows for the preferential retention of the target analyte. When the mobile phase conditions are properly adjusted, non-target analytes will remain bound to the stationary phase of the column or will be rapidly eluted from the column whereas the target molecule will be retained for a period of time sufficient to achieve separation between the target and non-target molecules. Since this strategy results in the consistent gradual migration of the target analyte through the column, a plurality of samples can be injected into a single gradient and the target analyte from each sample will elute in a time-resolved plurality of peaks whose order matches the sample injection order (Figure 3B ). Eventually, the column will require a reconditioning step, where a new solvent composition is used selected to elute and thereby clean bound moieties from the column. - Isocratic continuous elution is surprisingly useful for identifying the presence of the target compounds and analyzing complex biological samples, for example urine samples. Isocratic continuous LC allows sample-to-sample intervals of about 1 minute. The time interval between samples is affected by the column physical dimensions, the flow rate of the solvent, the chemical properties of the solvent, the chemical composition of the column stationary phase, the temperature of the column, the fluid pressure within the column, and the operational capabilities of the auto sampler (for example, the rate at which the instrumentation can perform repeat injections). Under typical analytical conditions, the time interval between eluting peaks from the target analytes will range from 30 to 90 seconds. This is a fraction of the time required for conventional gradient chromatography, as shown by comparison of
Figures 3A and3B . - Molecules eluting from the chromatographic setup are analyzed by spectrometry such as by NMR, mass spectrometry, UV-Vis, arrayed diode, etc. In one embodiment, liquid chromatography (LC) may be used in combination with mass spectrometry (MS). The combination LC-MS is a powerful tool used in medical sample analysis.
- As is illustrated in
Figure 4 , an inherent problem encountered when analyzing complex samples by LC-MS is that there may be differential ion suppression where different compounds, such as salt forms, elute from the column at different rates into the detector. Differential ion suppression refers to signal variation as a result of competition for ionization of analytes within the ion source. Differential ion suppression causes even the exact same sample to show up at different intensities when injected multiple times thereby limiting the accuracy and precision of LC-MS. InFigure 4 , for example, while twelve identical aliquots of a sample containing 5 uM 12C agmatine and 0.5 uM 13C agmatine (isotopically labelled) were successively injected to a column running an isocratic flow of solvent, the resulting MS signals varied 35-40%. In addition to affecting signal intensities, differential retention of interfering compounds can alter chromatographic peak shape and retention time of the target analyte. These quantitative and qualitative changes in chromatographic and ionization properties are substantially unaffected when compounds contain stable isotopes of carbon (13C) or nitrogen (15N). To control for variations in ionization and chromatographic properties, the present invention may employ isotope-labelled target compounds agmatine, putrescine or cadaverine, which allows for accurate and reliable detection of target compounds. - In one embodiment, therefore, isocratic continuous chromatographic elution is combined with a method in which a known concentration of an isotope-labeled version of the target analyte is added to each sample and concentrations of the target analyte are calculated from the observed ratio of 12C/13C signals. This isotope normalization strategy, also called isotope dilution, corrects for errors resulting from differential ion suppression because the target analyte and isotope-labeled target analyte co-elute and are thereby subjected to the same ionization and chromatographic conditions. As shown in
Figure 4 , for example, the ratio of signal intensities for successive analyses of 5 uM 12C agmatine to 0.5 uM 13C agmatine remained substantially consistent in each sample even though there was signal to signal variation for the same sample. Despite the variable ion suppression inherent to LC-MS,Figure 5 shows quantification of known concentrations of 12C agmatine using this isotope normalization method and demonstrates that robust quantification of target analyte levels can be achieved across a wide range of concentration values, including clinically relevant concentration values. In this example, the quantitative performance of the method was assessed using a panel of healthy urine samples that were spiked with a range of 12C agmatine standards and 100 nM U-13C agmatine as an internal reference. Injected samples were analysed by a column running isocratically and concentrations were calculated using a calibration curve shown inFigure 5 . The quantitative performance was assessed using an independent set of quality control samples. - Analysis of a urine sample can be spiked with a known concentration of an isotope of the target analyte, which in the case of the present method for detecting UTIs is one or more of agmatine, putrescine or cadaverine, and the signal intensity for the known concentration of isotope labelled target analyte can be employed to normalize quantitative variability and calculate the concentration of the target analyte. This method includes detecting both the target analyte and the simultaneously eluting isotope-labelled version of the target analyte and comparing their peak intensities. Using isocratic continuous elution and isotope dilution, the samples can be accurately analysed despite variability in ion suppression. This isotope dilution strategy enables target analytes to be accurately quantified in a plurality of urine samples injected sequentially into a continuous isocratic gradient.
- In another embodiment, chromatographic separation of analytes may include a two-stage, isocratic continuous elution to achieve good separation and close spacing of chromatographic peaks. This methodology is illustrated in
Figure 2C . For example, with reference toFigure 2C , the two-stage isocratic continuous chromatography method comprises: in the first stage, a first mobile phase is used to inject a plurality of samples onto the column followed by a second stage, where a second mobile phase is used to elute analytes off the column for analyte detection such as by MS. The second mobile phase has a composition different from the first mobile phase. The mobile phases may differ in hydrophobicity, solvent ionic strength, solvent composition, pH, etc. depending on the type of sample, the characteristics of the target compound, and the chemical and physical properties of the column's stationary phase. In the case of agmatine, the first mobile phase differs from the second mobile phase in terms of its hydrophobicity, where the first mobile phase is more hydrophobic than the second mobile phase. The first mobile phase is selected to provide a slow elution of the target analyte off the LC column. Thus, when samples are loaded onto the column, during the first stage, using the first mobile phase, the target analyte is substantially retained on the LC column. Once loaded, the second mobile phase allows for accelerated elution of the target analyte. - Two-stage isocratic chromatography enables analysis of target analytes from a plurality of samples by enabling multiple samples to be loaded onto a column in the first stage, then rapidly eluted during the second stage. The elution of all the samples in the second stage can occur in less, sometimes much less, time than the time taken for the sample injections in the first stage. The first mobile phase is selected for the target analyte to allow moderate binding of the analyte onto the column stationary phase such that analytes from a plurality of samples migrate through the column in a progressive series of peaks. The second mobile phase is selected to elute samples off the column rapidly, but substantially maintain the binding of non-target analytes. This two-stage strategy separates the target molecule in a plurality of samples while minimizing the amount of time necessary clear the column of target analytes. The second mobile phase enables analytes from a consecutive series of samples to be eluted in a much shorter time than is possible from a single stage of chromatography. Consequently, quantitative analysis of a series of samples loaded onto a column may be completed in a fraction of the time necessary to load the samples.
- To maintain fast chromatographic separation of target analytes over large number of samples, the two-stage isocratic continuous chromatography method can further include a multiplexed column injection schedule where a plurality of columns are employed (
Figures 1 and2D ). Each column can accept a number of samples that can be sequentially loaded until the column reaches its carrying capacity. This capacity is dictated by the physical and chemical properties of the column (e.g. 12 samples for the column used forFigure 8 ). Any potential timesavings through two-stage isocratic chromatography are restricted to analyses of samples in batches equal to or smaller than the carrying capacity of the column. However, multiplexing a plurality of columns allows timesavings to be extended to greater numbers of samples by sequentially loading, then eluting, target analytes off of a series of columns. Moreover, an apparatus enabling loading of multiple columns while simultaneously eluting another column could enable continuous analysis of large numbers of samples. - For example, as shown in
Figure 1 , a LC system may including two ormore columns mass spectrometer 12. This provides serial elution of samples off the plurality ofcolumns Figure 3C ). The columns may receive samples from the same source, for example, an auto-sampler 14 with samples a first mobile phase (dashed line). Bothcolumns elution pump 16. Avalve switch 18a may be used to switch communication between the sampler and each of the two columns while communication is also switched between the elution pump and the two columns. Anothervalve switch 18b may be provided at the output ends of the columns alternate communication of the detector to each of the first and second columns in turn. The valve switch directs eluting phases appropriately to either themass spectrometer 12 or to waste 20. The mobile phase coming off the column may be directed to waste during re-conditioning/equilibrium stages and any time the eluting mobile phase does not need to be analyzed by the detector. If a further mobile phase is required for reconditioning, a further supply may be added to and upstream of thevalve switch 18a, - In operation,
first column 10a may be injected with multiple samples using the first mobile phase, while a second column may elute analytes from the sample using a second mobile phase. Blocks of samples are injected on each column at different times. The basic premise of this aspect of the method is that a series of samples are injected onto the first column and then samples are eluted off the second column, where the injection and elution occurs in an alternating or sequential fashion on separate columns. In other words, the first column is in the first stage while the second column is in the second stage. This process is cycled, while one column elutes samples into the mass spectrometer, the other re-equilibrates and is loaded up with samples, for example by an auto-sampler. There many be a plurality of columns in the first stage, where blocks of samples are injected continuously onto the columns. There may be a plurality of columns in the second stage, where the samples are rapidly eluted off the columns. Thus, in a method according to the present invention, analysing includes a two-stage, isocratic continuous elution and a multiplexed column injection schedule. This achieves high sample throughput and good use of laboratory time and resources on an LC-MS platform for targeted compound detection in complex samples. - In the possible multiplexed column injection hardware set up as shown in
Figure 1 ,valve switch 18a may be used to switch the mobile phase being run on a column rapidly between two mobile phases: first mobile phase (dashed line) having a composition selected to be suitable for injection of samples, as from the auto-sampler; and second mobile phase (dotted line) configured to rapidly elute the target compound from the column, as fromelution pump 16. InFigure 1 , State A showsColumn 1 in the first stage andColumn 2 in the second stage; and State B, which has been switched over by thevalve switch 18a, showsColumn 1 is in the second stage andColumn 2 in first stage.Valve switch 18b at the eluted end of the columns alternately communicates eluted analytes from the two columns one at a time to the mass spectrometer. While two columns are shown inFigure 1 , it is to be understood that this method can employ more than two columns. - While the methods of chromatography have use apart from the methods for diagnosis of a UTI, the combination offers very high throughput of samples, as is particularly useful in medical laboratories. Consider that conventional gradient methods achieve an elution time peak to peak of about 2-4 minutes, an isocratic continuous system can usually achieve an elution time peak to peak of about 0.5-1.5 minutes, and a 2-stage, isocratic system can achieve an elution time peak to peak of less than one minute such as about 0.25-1 minute (
Figures 3A to 3C ). A multiplexed 2-stage system has overall even higher throughput since two or more columns can be accepting samples at the same time and feeding to one detector. Therefore, in another embodiment, isocratic continuous chromatography is used to detect the presence of at least one decarboxylated amino acid metabolite selected from agmatine, putrescine or cadaverine for diagnosing a patient suffering from a UTI, wherein culture-independent urine sample from the patient is analyzed by isocratic continuous chromatography. In another embodiment two-stage, isocratic continuous chromatography is used to detect the presence at least one decarboxylated amino acid metabolite selected from agmatine, putrescine or cadaverine for use in diagnosing a patient suffering from a UTI, wherein culture-independent urine samples from the patient is analyzed by two-stage, isocratic continuous chromatography. In another embodiment a multiplexed column injection schedule where a plurality of columns are employed and a two-stage, isocratic continuous chromatography is used to detect the presence at least one decarboxylated amino acid metabolite selected from agmatine, putrescine or cadaverine for use in diagnosing a patient suffering from a UTI, wherein culture-independent urine sample from the patients is analyzed by two-stage, isocratic continuous chromatography. - In another embodiment, analyzing a urine sample from the patient is achieved using LC-MS focusing on detection of agmatine. Agmatine has shown the highest level of ionization and highest predictive capacity relative to putrescine and cadaverine.
- Again, while a method is described for analysis of UTIs and specifically with respect to target analytes agmatine, putrescine or cadaverine, it is to be understood that the methods for LC described herein are useful for other applications for targeted compound detection in samples.
- A method for continuous isocratic chromatography was initially optimized using simulated UTI samples constructed from an unlabeled agmatine standard spiked into a healthy urine control sample. Optimal isocratic solvent composition for agmatine was determined to be 86% acetonitrile with 0.1% (v/v) formic acid, which allowed for high binding while still maintaining mobility of agmatine on the column to allow for quick plug spacing. An offset between binding and elution of about 4% was deemed beneficial to improve the chromatographic peak shape while expediting column elution and maintaining baseline separation between sample peaks, as shown in
Figure 3B . These conditions enabled serial injection with as little as 30 second spacing between peaks. Once optimal solvent ratio was determine, urine samples were injected with isotope-labelled 13C agmatine. - Urine samples were spiked with 13C agmatine and analyzed on a Thermo Q-Exactive™ HF LC-MS platform using a Syncronis™ HILIC column. A binary solvent system comprising 20 mM ammonium formate pH 3.00 (solvent A) and acetonitrile with 0.1% (v/v) formic acid (solvent B) was employed for chromatographic separation. Mass spectra were collected in positive ion mode using parallel reaction monitoring. Isotope diluted, two-stage, isocratic continuous elution with a multiplexed column injection schedule analyses were conducted by i) serially injecting isotope-tagged urine samples in a continuous 86% solvent B (first mobile phase) isocratic flow and ii) eluting the serial sample plugs using an isocratic step at 82% solvent B (second mobile phase). Hardware including a switch valve (
Figure 1 ) ensured that step i) was conducted in the first column while step ii) was conducted in the second column and that the solvent was immediately changed when changing the elution from first mobile phase to second mobile phase and back to the first mobile phase, in an alternating fashion. Differential ion suppression was controlled by quantifying the isotope ratio between native agmatine metabolites versus the coeluting 13C standards. - A sample of urine spiked with 5 uM 12C and 500 nm U-13C agmatine is injected 12 times in a row using isocratic continuous chromatography. Note how the signal errors (illustrated by signal to signal variance) for both the target compound, specifically agmatine and the isotope-labelled agmatine are the same for each sample. Thus, computing the concentration of the 12C analyte from the observed ratio of 12C versus 13C signals cancels out error term, for example differential ion suppression, which may be caused by variations in ionization or chromatography sample-to-sample. This method enables the concentrations of analytes to be accurately determined despite significant sample-to-sample and column-to-column variability in the performance of the detection system.
- While shown above for urine analysis, the present method is also applicable for other systems. This is however not claimed. For example, as shown in
Figure 6 , two-stage, isocratic continuous chromatography was used to distinguish nine microbial cultures of P. aeruginosa (Pae) from Escherichia coli (Eco). P. aeruginosa does not produce putrescine whereas Escherichia coli produces significant levels of putrescine under the microbial culture conditions used for this assay. Consequently, cultures growing Escherichia coli could be differentiated from cultures growing P. aeruginosa on the basis of putrescine levels observed in the samples. As shown inFigure 6 , there are nine peaks detected, representing the nine urine samples and three blocks of peaks eluting over time, representing three technical replications that were performed demonstrating the stability and reliability of the method. The microbial culture example used here illustrates the general applicability of the method for microbial analyses. Moreover, the microbial culture conditions used for this study are similar to those used in analysis of bloodstream infections (BSIs) and thereby indicate the applicability of the method to other clinical applications, including detection of BSIs. - Following optimization, a cohort of ninety-six urine samples from patients with and without urinary tract infections (UTIs) were analyzed under two conditions: i) Example IA, namely isotope-labelled, isocratic continuous chromatography (
Figure 7 ); and ii) Example IB, namely isotope-labelled, two-stage, isocratic continuous chromatography with a multiplexed column injection schedule (Figure 8 ). This study produced promising results. The method of quantification by isotope ratio achieved error rates comparable to those observed in more traditional 15 minute linear gradients. - In particular, a set of ninety-six urine samples from patients suffering from UTls, specifically Escherichia coli are shown compared to ninety-six urine samples from healthy patients. The bottom chart of
Figures 7 and8 shows the detection of isotope labelling of 13C agmatine, the upper left chart ofFigures 7 and8 shows ninety-six urine samples which tested negative for a UTI and the upper right chart ofFigures 7 and8 shows ninety-six urine samples which tested positive for Escherichia coli. InFigure 7 , the samples were analyzed by isocratic continuous chromatography according to the methodology described in Example IA and inFigure 8 , the samples were analyzed by two-stage, isocratic continuous chromatography with a multiplexed column injection schedule according to the methodology described in Example IB. Each ofFigures 7 and8 show negative urine samples (no infection by UTI-causing microorganisms) on the upper left hand chart and Escherichia coli-infected urine samples on the upper right hand chart. - These data suggest that both isocratic continuous chromatography and two-stage, isocratic continuous chromatography with a multiplexed column injection schedule could provide feasible strategies for high-throughput quantitative analyses of select biomarkers. Moreover, the methods were directly applicable to the detection of UTIs.
- It is noted from comparing the results from
Figure 7 and8 that two-stage, isocratic continuous chromatography with a multiplexed column injection schedule (Figure 8 ) provides shorter run times for sample detection than isocratic continuous chromatography (Figure 7 ). It was noted that using isocratic continuous chromatography a sample per minute to a sample per 30 seconds could be detected whereas the sample elution/detection times were further compressed using two-stage, isocratic continuous chromatography with a multiplexed column injection schedule. - In order to validate the methods of the invention, a blinded cohort of urine samples from patients were subjected to two-stage, isocratic continuous chromatography with a multiplexed column injection schedule to detect native agmatine content. The patient urine samples were separately analyzed via traditional UTI diagnostic methods. Using only agmatine, the data suggests that agmatine presence in uncultured or culture-independent urine samples can diagnose roughly 85% of patients that present clinically with a bacterial urinary tract infection. In this study, 192 patient samples were submitted to multicolumn, two-stage and isocratic continuous chromatography analysis as in Example IB. The overall run time was 430 minutes, which included 192 patient samples with two technical replicates and a number of quality control blank injections providing 448 total injections. This averages out to an average run time of 1.1 minutes per patient sample overall and 0.96 minutes per injection. Of the 192 patient samples, only one false positive was observed. The false positive was likely a product of differences between the internal positivity threshold and that of the traditional microbiology assay. All false negatives were expected, coming from microbes that are not known to produce agmatine in urine. Overall this is an extremely fast and effective screen compared to conventional detection methodologies that if implemented would have a significant impact on the speed of diagnosis of UTIs as well as circumvent the need to
culture 85% of patient samples. Only the negative samples would have to be cultured for confirmation of bacterial UTI. - Urine samples are typically collected in urine culture tubes containing a buffered boric acid solution that minimizes microbial growth during sample transport to the microbiology laboratory. To assess the impact of growth preservatives on agmatine production, seven strains of Escherichia coli (MG1665, ATCC 25922, ESBL ATCC BAA-196, and 4 clinical isolates) were seeded in Mueller Hinton medium overnight, and subcultured in filter-sterilized urine with or without preservatives (boric acid, 2.63mg/mL; sodium borate, 3.95mg/mL; sodium formate, 1.65mg/mL). Bacterial samples were seeded at 105 CFU/mL in respective medium in a 96-well plate and incubated statically at 37°C in the presence of 5% CO2. Growth was monitored (OD600nm) using a Microskan GO plate reader (Thermo Scientific, Waltham, MA). Samples for MS were first centrifuged (4200g, 10 min, at 4°C) to pellet out microbes. Supernatant was then diluted 1:1 in MeOH, and stored at -20°C. Samples were thawed, and immediately re-centrifuged (4200g, 10 min, at 4°C) to precipitate out any residual proteins, and diluted in 50% MeOH to a final dilution of 1:20. Samples were analyzed on a Q Exactive™ HF Mass Spectrometer (Thermo Scientific, Waltham, MA). LC-MS analysis showed that the concentration of agmatine in the sample was effectively the same after the incubation time with the preservative as it was immediately before contact with the preservative; no significant microbial growth or agmatine production were detected over this incubation in samples containing a boric acid preservative solution whereas significant growth and agmatine production were observed in samples that did not include the preservative. Consequently, it was found that the boric acid preservative solution substantially inhibited both microbial growth and agmatine production over sample storage timelines consistent with clinical practice. It was determined that standard urine sample collection in a boric acid tube would not influence agmatine concentration in the sample.
- A cohort of Escherichia coli positive urine samples with a diverse range of susceptibility profiles were analyzed by metabolic preference assay. Bacteria from these samples were pelleted, washed, and re-suspended in equal volumes of Mueller Hinton medium. 96-well plates were seeded with 10% of the washed cells, were incubated for four hours in the presence or absence of clinically relevant concentrations of antibiotics, and were analyzed by LC-MS (
Figure 10 ). Metabolic preference assay based diagnostics closely recapitulated the antibiotic susceptibility profiles reported via the traditional culture-based approach. There was substantial agreement between the breakpoints determined by metabolic preference assay based and traditional culture-based approaches for the antibiotics. The metabolic preference assay strategy correctly assigned antibiotic susceptibilities in 97% of samples. - To assess the performance of agmatine as a predictor of UTIs, a data set of 519 urine samples obtained from Alberta Public Laboratories was analyzed. This data revealed that native agmatine concentrations were tightly linked to culture positive samples containing Enterobacteriaceae (
Figure 11 ). All 11 Enterobacteriaceae species observed in the data set produced agmatine at a median concentration of 2.1 µM, whereas no detectable agmatine was present in the culture-negative samples or those classified as doubtful clinical significance by Alberta Public Laboratories (Figure 11 ). Although a large percentage of UTIs are caused by Enterobacteriaceae, a small proportion of UTls result from other microbes. The data set included a limited number of these organisms, none of which produced detectable levels of agmatine. Using the data set, a diagnostic agmatine threshold of about 0.17 µM for differentiating culture-negative versus culture-positive samples was calculated. This threshold was calibrated to correspond to about 97% specificity and 94% sensitivity for the detection of Enterobacteriaceae-linked UTIs. - Urine samples in 50% methanol (1.2 mL) were centrifuged at 14,800g for five minutes. From these samples, 800 µL of urine was added to 200 µL isotope-dilution solution of 1 µM [U-13C] agmatine and 100 mM ammonium bicarbonate (pH 8.0) in 50% methanol for a final concentration of 200 nM [U-13C] agmatine and 20 mM ammonium bicarbonate. Thermo Scientific HyperSep Silica 96-well plates (25 mg bed volume, 1 mL column capacity) were pre-equilibrated with 400 µL HPLC-grade methanol followed by 400 µL 50% HPLC-grade methanol/H2O. Following equilibration, the 1 mL prepared sample was added to the column and allowed to drip through. Next, a methanol wash was conducted with 1 mL HPLC methanol followed by a water wash with 1 mL HPLC water. All of the solutions used in the washing steps were assisted through the columns by centrifugal force (20g for 5 min). The column was then primed by adding 250 µL of 99.9% methanol with 0.1% formic acid. To elute the molecules of interest, 125 µL H2O with 2% formic acid was allowed to drip through the column. Ammonium bicarbonate (pH = 8.0) was added to a final concentration of 100 mM in order to raise the solution to a pH > 3.0 prior to LC-MS/MS analysis. Note: the first set of 196 samples contained a 13C agmatine concentration of 100 nM and a final volume of 500 µL.
- The previous description and examples are to enable the person of skill to better understand the invention. The invention is not be limited by the description and examples, but instead the scope of the invention is defined by the appended claims.
Claims (11)
- A method of diagnosing a urinary tract infection UTI in a patient, the method comprising:receiving a urine sample from the patient;analyzing the urine sample; andwherein the patient is diagnosed as having the UTI if a threshold concentration of greater than 170 nM agmatine is detected in the urine sample.
- The method of diagnosing of claim 1, wherein analyzing the sample includes separating analytes in the urine using liquid chromatography LC.
- The method of diagnosing of claim 2, wherein analyzing includes operating the liquid chromatography using an isocratic solvent for elution of the agmatine.
- The method of diagnosing of any one of claims 1-3, wherein the agmatine is detected using mass spectrometry.
- The method of diagnosing of any one of claims 2-4, wherein analyzing further includes a two-stage isocratic continuous LC to achieve separate chromatographic peaks, the two-stage isocratic continuous LC including: in a first stage, a first mobile phase used to inject the plurality of samples onto a LC column followed by a second stage, where a second mobile phase different than the first mobile phase is used to elute analytes off the LC column.
- The method of diagnosing of claim 5, wherein analyzing further includes two-stage isocratic continuous LC with a multiplexed column injection schedule, the multiplexed column injection schedule including a plurality of LC columns.
- The method of diagnosing in any one of claims 1-6, wherein analyzing further includes adding a known quantity of an isotopically labelled version of agmatine into the urine sample for determining a concentration of agmatine.
- The method of diagnosing of claim 1, further comprising diagnosing a plurality of patients and analyzing a plurality of samples continuously by a liquid chromatography - mass spectrometry, LC-MS apparatus wherein a LC is run with an isocratic solvent.
- The method of diagnosing of any one of claims 4-8, wherein the isocratic solvent is acetonitrile and formic acid.
- The method of diagnosing of claim 1 further comprising: incubating the urine sample in a growth medium; after incubation, analyzing the incubated growth medium by chemical analysis to determine a level of each of one or more metabolites in the incubated growth medium; and identifying a type of Enterobacteriaceae bacteria causing the UTI by comparison of the level of each of the one or more metabolites with reference metabolite profiles and matching the level of each of the one or more metabolites with a reference metabolite profile indicative of the type of Enterobacteriaceae bacteria.
- The method of diagnosing of claim 1 further comprising selecting an antibiotic to be active against an Enterobacteriaceae bacterium.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862679565P | 2018-06-01 | 2018-06-01 | |
PCT/CA2019/050763 WO2019227235A1 (en) | 2018-06-01 | 2019-05-31 | Method for detecting urinary tract infections and sample analysis using liquid chromatography |
Publications (4)
Publication Number | Publication Date |
---|---|
EP3803390A1 EP3803390A1 (en) | 2021-04-14 |
EP3803390A4 EP3803390A4 (en) | 2022-03-09 |
EP3803390B1 true EP3803390B1 (en) | 2024-05-01 |
EP3803390C0 EP3803390C0 (en) | 2024-05-01 |
Family
ID=68696613
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19811477.9A Active EP3803390B1 (en) | 2018-06-01 | 2019-05-31 | Method for detecting urinary tract infections and sample analysis |
Country Status (6)
Country | Link |
---|---|
US (1) | US20210215668A1 (en) |
EP (1) | EP3803390B1 (en) |
CN (1) | CN112513632A (en) |
AU (1) | AU2019275957A1 (en) |
CA (1) | CA3102113C (en) |
WO (1) | WO2019227235A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111948313B (en) * | 2020-08-12 | 2022-09-23 | 贵州省兽药饲料检测所(贵州省兽药残留监测中心) | Method for determining content of trimethoprim and multiple sulfanilamide drugs in drug and application thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3816883B2 (en) * | 2003-03-06 | 2006-08-30 | 株式会社日立ハイテクノロジーズ | Liquid chromatograph mass spectrometer |
EP2517022A4 (en) * | 2009-12-22 | 2013-07-10 | Univ Michigan | Metabolomic profiling of prostate cancer |
SE539566C2 (en) * | 2014-09-03 | 2017-10-10 | Danell Nils | Device for the detection of gaseous amines from disease in the human urogential system |
-
2019
- 2019-05-31 AU AU2019275957A patent/AU2019275957A1/en active Pending
- 2019-05-31 CA CA3102113A patent/CA3102113C/en active Active
- 2019-05-31 CN CN201980047248.4A patent/CN112513632A/en active Pending
- 2019-05-31 US US15/734,163 patent/US20210215668A1/en active Pending
- 2019-05-31 WO PCT/CA2019/050763 patent/WO2019227235A1/en unknown
- 2019-05-31 EP EP19811477.9A patent/EP3803390B1/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP3803390A1 (en) | 2021-04-14 |
WO2019227235A1 (en) | 2019-12-05 |
CN112513632A (en) | 2021-03-16 |
EP3803390C0 (en) | 2024-05-01 |
AU2019275957A1 (en) | 2021-01-07 |
CA3102113C (en) | 2022-10-18 |
US20210215668A1 (en) | 2021-07-15 |
EP3803390A4 (en) | 2022-03-09 |
CA3102113A1 (en) | 2019-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Vuckovic | Current trends and challenges in sample preparation for global metabolomics using liquid chromatography–mass spectrometry | |
Soule et al. | Environmental metabolomics: Analytical strategies | |
CN110554123A (en) | Method and kit for rapidly detecting immunosuppressant in whole blood and application of kit | |
KR20150122191A (en) | Method to identify bacterial species by means of gas chromatography/mass spectrometry in biological samples | |
US20170205426A1 (en) | Rapid mass spectrometry methods for antimicrobial susceptibility testing using top-down mass spectrometry | |
Six et al. | Advances and challenges in bacterial compound accumulation assays for drug discovery | |
Kok et al. | Current status of matrix-assisted laser desorption ionisation-time of flight mass spectrometry in the clinical microbiology laboratory | |
Crowther et al. | Multiomics tools for the diagnosis and treatment of rare neurological disease | |
US20200010870A1 (en) | Device, Method, And System For Identifying Organisms And Determining Their Sensitivity To Toxic Substances Using The Changes In The Concentrations Of Metabolites Present In Growth Medium | |
Wang et al. | Simultaneous determination of 10 kinds of biogenic amines in rat plasma using high‐performance liquid chromatography coupled with fluorescence detection | |
Shen et al. | Quantitative metabolic network profiling of Escherichia coli: An overview of analytical methods for measurement of intracellular metabolites | |
EP3803390B1 (en) | Method for detecting urinary tract infections and sample analysis | |
CN110632214B (en) | Method for measuring histamine content in gentamicin sulfate for animals | |
Zhong et al. | A quantitative metabolomics study of bacterial metabolites in different domains | |
CN114174527A (en) | Metabonomics characterization of microorganisms | |
WO2018042454A2 (en) | Method of hyperplexing in mass spectrometry to elucidate temporal dynamics of proteome | |
CN114577916A (en) | Analysis method of stable isotope labeling metabolic flow based on chip nanoliter electrospray mass spectrum | |
Pablo et al. | Analysis of Busulfan in Plasma by Liquid Chromatography‐Tandem Mass Spectrometry (LC‐MS/MS) | |
Lo et al. | Identification of microbial mixtures by LC‐selective proteotypic‐peptide analysis (SPA) | |
Alberto et al. | Differences between biogenic amine detection by HPLC methods using OPA and dansyl derivates | |
Gika et al. | The role of mass spectrometry in nontargeted Metabolomics | |
JP4584767B2 (en) | Protein proteome quantitative analysis method and apparatus | |
CN114624317B (en) | Qualitative and quantitative analysis method based on direct sample injection mass spectrum | |
CA2875331C (en) | Methods for diagnosing chronic valvular disease | |
CN116519830A (en) | Genetic metabolic disease screening method, system and device based on gas chromatograph-mass spectrometer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20201223 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
REG | Reference to a national code |
Ref document number: 602019051550 Country of ref document: DE Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: G01N0033493000 Ipc: G01N0030880000 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20220207 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: G01N 30/46 20060101ALN20220201BHEP Ipc: G01N 30/72 20060101ALN20220201BHEP Ipc: G01N 33/50 20060101ALI20220201BHEP Ipc: G01N 33/48 20060101ALI20220201BHEP Ipc: G01N 33/493 20060101ALI20220201BHEP Ipc: G01N 30/88 20060101AFI20220201BHEP |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20240124 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602019051550 Country of ref document: DE |
|
U01 | Request for unitary effect filed |
Effective date: 20240513 |
|
U07 | Unitary effect registered |
Designated state(s): AT BE BG DE DK EE FI FR IT LT LU LV MT NL PT SE SI Effective date: 20240523 |
|
U20 | Renewal fee paid [unitary effect] |
Year of fee payment: 6 Effective date: 20240521 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20240612 Year of fee payment: 6 |